You just read:

FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma

News provided by

EMD Serono

Feb 11, 2019, 17:44 ET